(CSX) CSX - Overview
Stock: Rail, Intermodal, Bulk, Chemicals, Automotive
| Risk 5d forecast | |
|---|---|
| Volatility | 22.0% |
| Relative Tail Risk | -2.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.22 |
| Alpha | 17.80 |
| Character TTM | |
|---|---|
| Beta | 0.780 |
| Beta Downside | 1.026 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.44% |
| CAGR/Max DD | 0.45 |
EPS (Earnings per Share)
Revenue
Description: CSX CSX March 03, 2026
CSX Corporation (NASDAQ: CSX) operates a rail-based freight network across the eastern United States and parts of Canada, complemented by a trucking segment that handles intermodal transfers, drayage, and bulk-commodity moves. Its service portfolio spans chemicals, agricultural products, minerals, automotive goods, and coal shipments to power plants and steel mills, as well as a 30-terminal intermodal system for consumer-goods containers.
The company’s infrastructure includes roughly 20,000 route-mile rail lines serving 26 states east of the Mississippi River, the District of Columbia, and the Canadian provinces of Ontario and Quebec, supported by a fleet of about 3,400 locomotives. CSX also operates distribution centers and storage sites for automotive customers and provides rail-to-truck connections for non-rail-served shippers such as plastics and ethanol producers.
In FY 2025 CSX reported revenue of $13.3 billion and an operating ratio of 60.5%, an improvement of 0.7 points year-over-year, while net income rose to $2.1 billion. Intermodal volumes grew 7% YoY, driven by continued reshoring of supply chains and higher consumer-goods demand, and total traffic increased 5% on the back of robust construction and energy-sector activity. The company is allocating roughly $1.5 billion in 2026 capital expenditures to modernize track, expand terminal capacity, and enhance locomotive efficiency, supporting its target dividend yield of about 2.8%.
For a deeper dive into CSX’s valuation metrics and how they compare within the rail-transport sector, you might want to explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 2.89b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.65 > 1.0 |
| NWC/Revenue: -17.44% < 20% (prev -3.14%; Δ -14.31% < -1%) |
| CFO/TA 0.11 > 3% & CFO 4.61b > Net Income 2.89b |
| Net Debt (18.20b) to EBITDA (6.29b): 2.89 < 3 |
| Current Ratio: 0.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.86b) vs 12m ago -2.97% < -2% |
| Gross Margin: 33.25% > 18% (prev 0.37%; Δ 3288 % > 0.5%) |
| Asset Turnover: 32.60% > 50% (prev 34.00%; Δ -1.40% > 0%) |
| Interest Coverage Ratio: 5.47 > 6 (EBITDA TTM 6.29b / Interest Expense TTM 844.0m) |
Altman Z'' 1.50
| A: -0.06 (Total Current Assets 675.0m - Total Current Liabilities 3.13b) / Total Assets 43.68b |
| B: 0.24 (Retained Earnings 10.56b / Total Assets 43.68b) |
| C: 0.11 (EBIT TTM 4.61b / Avg Total Assets 43.22b) |
| D: 0.35 (Book Value of Equity 10.56b / Total Liabilities 30.52b) |
| Altman-Z'' Score: 1.50 = BB |
Beneish M -2.95
| DSRI: 0.71 (Receivables 909.0m/1.33b, Revenue 14.09b/14.54b) |
| GMI: 1.10 (GM 33.25% / 36.70%) |
| AQI: 1.48 (AQ_t 0.13 / AQ_t-1 0.09) |
| SGI: 0.97 (Revenue 14.09b / 14.54b) |
| TATA: -0.04 (NI 2.89b - CFO 4.61b) / TA 43.68b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of CSX shares?
Over the past week, the price has changed by -3.20%, over one month by +3.55%, over three months by +13.73% and over the past year by +35.11%.
Is CSX a buy, sell or hold?
- StrongBuy: 11
- Buy: 5
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CSX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40.6 | -1.3% |
| Analysts Target Price | 40.6 | -1.3% |
CSX Fundamental Data Overview March 06, 2026
P/E Forward = 23.0947
P/S = 5.6452
P/B = 6.0331
P/EG = 3.6274
Revenue TTM = 14.09b USD
EBIT TTM = 4.61b USD
EBITDA TTM = 6.29b USD
Long Term Debt = 18.16b USD (from longTermDebt, last quarter)
Short Term Debt = 708.0m USD (from shortTermDebt, last quarter)
Debt = 18.87b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.20b USD (from netDebt column, last quarter)
Enterprise Value = 97.75b USD (79.55b + Debt 18.87b - CCE 675.0m)
Interest Coverage Ratio = 5.47 (Ebit TTM 4.61b / Interest Expense TTM 844.0m)
EV/FCF = 24.83x (Enterprise Value 97.75b / FCF TTM 3.94b)
FCF Yield = 4.03% (FCF TTM 3.94b / Enterprise Value 97.75b)
FCF Margin = 27.93% (FCF TTM 3.94b / Revenue TTM 14.09b)
Net Margin = 20.50% (Net Income TTM 2.89b / Revenue TTM 14.09b)
Gross Margin = 33.25% ((Revenue TTM 14.09b - Cost of Revenue TTM 9.41b) / Revenue TTM)
Gross Margin QoQ = 31.64% (prev 34.88%)
Tobins Q-Ratio = 2.24 (Enterprise Value 97.75b / Total Assets 43.68b)
Interest Expense / Debt = 1.13% (Interest Expense 213.0m / Debt 18.87b)
Taxrate = 21.74% (200.0m / 920.0m)
NOPAT = 3.61b (EBIT 4.61b * (1 - 21.74%))
Current Ratio = 0.22 (Total Current Assets 675.0m / Total Current Liabilities 3.13b)
Debt / Equity = 1.43 (Debt 18.87b / totalStockholderEquity, last quarter 13.16b)
Debt / EBITDA = 2.89 (Net Debt 18.20b / EBITDA 6.29b)
Debt / FCF = 4.62 (Net Debt 18.20b / FCF TTM 3.94b)
Total Stockholder Equity = 12.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.68% (Net Income 2.89b / Total Assets 43.68b)
RoE = 22.90% (Net Income TTM 2.89b / Total Stockholder Equity 12.62b)
RoCE = 14.99% (EBIT 4.61b / Capital Employed (Equity 12.62b + L.T.Debt 18.16b))
RoIC = 11.39% (NOPAT 3.61b / Invested Capital 31.69b)
WACC = 7.10% (E(79.55b)/V(98.42b) * Re(8.57%) + D(18.87b)/V(98.42b) * Rd(1.13%) * (1-Tc(0.22)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.70%
[DCF] Terminal Value 80.67% ; FCFF base≈3.45b ; Y1≈3.24b ; Y5≈3.02b
[DCF] Fair Price = 25.20 (EV 65.06b - Net Debt 18.20b = Equity 46.86b / Shares 1.86b; r=7.10% [WACC]; 5y FCF grow -7.90% → 2.90% )
EPS Correlation: -58.93 | EPS CAGR: 0.0% | SUE: -1.02 | # QB: 0
Revenue Correlation: -47.24 | Revenue CAGR: 0.73% | SUE: -1.20 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.49 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=-6 | Analysts=22
EPS current Year (2026-12-31): EPS=1.85 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=-21 | Growth EPS=+14.8% | Growth Revenue=+2.8%
EPS next Year (2027-12-31): EPS=2.09 | Chg7d=+0.001 | Chg30d=-0.000 | Revisions Net=-10 | Growth EPS=+12.9% | Growth Revenue=+4.6%
[Analyst] Revisions Ratio: -0.60 (2 Up / 8 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 8.6% - Earnings Yield 3.6%)
[Growth] Growth Spread = -2.7% (Analyst 2.2% - Implied 5.0%)